Sensei Biotherapeutics, a cancer-focused biotech with offices in the Seaport, announced this week it will shed about 65% of its staff while evaluating a potential sale.

As of March 14, 2025, the company had 14 full-time employees and one part-time employee. After the layoffs, about five employees will remain to explore strategic alternatives, handle regulatory and financial reporting requirements, and wind down development activities.

According to its annual report, the latest layoffs follow a restructuring last November, when the company cut 46% of its staff to streamline operations and concentrate resources on advancing its lead product, the monoclonal antibody solnerstotug.

As part of the restructuring, the company closed its research site in Rockville, Maryland, focusing on its of

See Full Page